Potential cost savings associated with dose rounding antineoplastic monoclonal agents

Journal of Oncology Pharmacy Practice

Volumn 21, Issue 4, 2015, Pages 280-284

  Francis, Sarah M ^a   Heyliger, Alexander ^a   Miyares, Marta A ^b   Viera, Marcos ^b  

^a NOVA SOUTHEASTERN UNIVERSITY   (United States)

^b JACKSON MEMORIAL HOSPITAL   (United States)

Author keywords

antineoplastic monoclonal agents; Cost savings; dose rounding

Indexed keywords

BEVACIZUMAB; CETUXIMAB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; COLON CANCER; CONSULTATION; COST CONTROL; DRUG COST; DRUG DOSE REDUCTION; ELECTRONIC MEDICAL RECORD; ESOPHAGUS CANCER; HOSPITAL PATIENT; HUMAN; OUTPATIENT; PERITONEUM PSEUDOMYXOMA; PRIORITY JOURNAL; PROSTATE CANCER; RECTUM CANCER; STOMACH CANCER; DOSE RESPONSE; ECONOMICS; NEOPLASMS; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BEVACIZUMAB; CETUXIMAB; COST SAVINGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HUMANS; NEOPLASMS; TRASTUZUMAB;

EID: 84936997835     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155214533369     Document Type: Article

References (19)

1. Fact Book Fiscal Year 2012. National Heart, Lung, and Blood Institute. US Department of Health & Human Services, http://www.nhlbi.nih.gov/about/factbook/FactBook2012.pdf (accessed 18 Aug 2013).
2. Cancer Facts & Figures 2014. American Cancer Society, http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014 (2014, accessed 28 Mar 2014).
3. Shaughnessy AF,. Monoclonal antibodies: magic bullets with a hefty price tag. Brit Med J 2012; 345: e8346-e8346.
4. Biosimilar/Follow-on Biologics Market Report & Forecast: a Focus on the US (2011-2020). International Market Analysis Research and Consulting Group. Delhi, India. October 2011.
5. Winger BJ, Clements EA, Deyoung JL,. Cost savings from dose rounding of biologic anticancer agents in adults. J Oncol Pharm Pract 2011; 17: 246-251.
6. Dooley MJ, Singh S, Michael M,. Implications of dose rounding of chemotherapy to the nearest vial size. Support Care Cancer 2004; 12: 653-656.
7. 'Rounding down' select chemotherapy doses preserves vials, yields substantial cost savings. Formulary 2000; 35: 369.
8. Field K, Zelenko A, Kosmider S,. Dose rounding of chemotherapy in colorectal cancer: an analysis of clinician attitudes and the potential impact on treatment costs. Asia Pac J Clin Oncol 2010; 6: 203-209.
9. Fasola G, Aita M, Marini L,. Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study. BMC Health Serv Res 2008; 8: 70-70.
10. Avastin (package insert). South San Francisco, CA: Genentech Inc, 2013.
11. Herceptin (package insert). San Francisco, CA: Genetech Inc, 2010.
12. Erbitux (package insert). Princeton, NJ: Bristol-Myers Squibb, 2012.
13. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Palliative Care, v.2.2013, http://www.nccn.org/professionals/physician-gls/pdf/palliative.pdf (accessed 1 August 2013).
14. Harrington SE,. The role of chemotherapy at the end of life: “When Is Enough, Enough?�. J Amer Med Assoc 2008; 299: 2667-2678.
15. Phillips, Ayanna. Chemotherapy dose rounding -survey results [online forum comment], www.uhc.edu (accessed 10 June 2009).
16. US Pharmacopeial Convention: USP 34/NF 29: Antimicrobial effectiveness testing-USP General Chapter -51. www.usp.org/usp-nf (accessed 1 August 2013).
17. De prijck K, D'haese E, Vandenbroucke J,. Microbiological challenge of four protective devices for the reconstitution of cytotoxic agents. Lett Appl Microbiol 2008; 47: 543-548.
18. Rowe EC, Savage SW, Rutala WA,. Economic and microbiologic evaluation of single-dose vial extension for hazardous drugs. J Oncol Pract 2012; 8: e45-e49.
19. Pouliquen AL, Escalup L, Jourdan N,. Dose standardisation of anticancer drugs. Int J Clin Pharm 2011; 33: 221-228.